Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B-IgG-SAP (Blank-IgG-Saporin) is a non-targeted immunotoxin conjugate primarily utilized as a negative control in preclinical research, particularly in molecular neurosurgery and neurobiology. It consists of a non-specific immunoglobulin G (IgG) antibody—most commonly mouse IgG—covalently conjugated to saporin, a Type I ribosome-inactivating protein (RIP) derived from the soapwort plant (*Saponaria officinalis*). Saporin acts as an RNA N-glycosidase that irreversibly depurinates the sarcin/ricin loop of the 28S ribosomal RNA, thereby halting protein synthesis and inducing apoptotic cell death. Because the IgG component of B-IgG-SAP lacks a specific binding affinity for cell-surface receptors, the conjugate does not undergo efficient receptor-mediated endocytosis in healthy cells. It is used to establish a baseline for non-specific cellular uptake, the inherent toxicity of the saporin payload, and the physical effects of the administration procedure in experimental models of neurodegenerative conditions, such as Alzheimer's disease, where targeted conjugates like 192-IgG-SAP are employed to lesion specific neuronal populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on B-IgG-SAP.